Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 5Suspended 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma, Follicular 1Glioblastoma 1Astrocytoma 1

Interventions

Specimen Handling 33Magnetic Resonance Spectroscopy 21Biopsy 19Cyclophosphamide 10venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Vincristine 5Etoposide 5Bevacizumab 5fludarabine phosphate 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Injections 4Doxorubicin 4Cisplatin 4fludarabine 3durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Leucovorin 3Irinotecan 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 1 year × Clear all
NCT06860594 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡